Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
17.5M
-
Shares change
-
-578K
-
Total reported value, excl. options
-
$110M
-
Value change
-
-$23.3M
-
Number of buys
-
33
-
Number of sells
-
-19
-
Price
-
$6.31
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q4 2018
69 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q4 2018.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.5M shares
of 77.3M outstanding shares and own 22.57% of the company stock.
Largest 10 shareholders include venBio Select Advisor LLC (2.4M shares), BVF INC/IL (1.79M shares), Vivo Capital, LLC (1.41M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.3M shares), Capital World Investors (964K shares), Aquilo Capital Management, LLC (952K shares), Capital International Investors (937K shares), CITADEL ADVISORS LLC (838K shares), Point72 Asset Management, L.P. (725K shares), and ORBIMED ADVISORS LLC (635K shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.